Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system
Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system
复制标题
DOI：
10.1099/jmm.0.46493-0
复制
发表时间：
2006-06-01
影响因子：
3
通讯作者：
Chen, Zhi
中科院分区：
文献类型：
--
作者：
Jiang, Han-Liang;Zhu, Hai-Hong;Chen, Zhi
人乳头瘤病毒（HPV）感染是宫颈癌的主要原因，宫颈癌是大多数发展中国家妇女的主要癌症。分子流行病学证据清楚地表明，某些类型的HPV是浸润性宫颈癌和宫颈上皮内瘤变的主要原因。然而，目前还没有针对HPV的全面、高通量分型检测方法。通过结合L1共识PCR和多重杂交，使用基于Luminex xMAP系统的悬浮阵列，作者开发了一种快速高通量检测方法，HPV DNA悬浮阵列（HPV-SA），能够同时分型26种HPV，包括18种高危HPV基因型和8种低危HPV基因型。评价了应用于26个合成寡核苷酸靶标的HPV-SA的性能。HPV-SA系统完美区分了18种高危HPV靶标和8种低危HPV靶标。为了评估该检测方法的临床适用性，对133份MY 09/MY 11引物组介导的PCR（MY-PCR）阳性临床标本进行了HPV-SA检测;在133份样本中，121份HPV-SA检测结果为阳性。单一和多种类型都很容易识别。作者认为，该检测方法的改进可能有助于流行病学研究，癌症筛查计划，治疗干预措施的监测以及HPV疫苗试验有效性的评估。
Infection with human papillomavirus (HPV) is the main cause of cervical cancer, the principal cancer in women in most developing countries. Molecular epidemiologic evidence clearly indicates that certain types of HPV are the principal cause of invasive cervical cancer and cervical intraepithelial neoplasia. Comprehensive, high-throughput typing assays for HPV, however, are not currently available. By combining L1 consensus PCR and multiplex hybridization using a Luminex xMAP system-based suspension array, the authors developed a rapid high-throughput assay, the HPV DNA suspension array (HPV-SA), capable of simultaneously typing 26 HPVs, including 18 high-risk HPV genotypes and eight low-risk HPV genotypes. The performance of the HPV-SA applied to 26 synthetic oligonucleotide targets was evaluated. The HPV-SA system perfectly discriminated 18 high-risk HPV targets from eight low-risk HPV targets. To assess the clinical applicability of the assay, the HPV-SA was performed with 133 MY09/MY11 primer set-mediated PCR (MY-PCR)-positive clinical specimens; of the 133 samples, 121 were positive by HPV-SA. Both single and multiple types were easily identified. The authors believe that improvement of the assay may be useful for epidemiological studies, cancer-screening programmes, the monitoring of therapeutic interventions, and the evaluation of the efficacy of HPV vaccine trials.